Study of the medicinal product Trabectedin in Patients with AdvancedBreast Carcinoma.
Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderma Pigmentosum G Gene (XPG) Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Recepto ...
Advanced Breast Carcinoma MedDRA version: 14.0;Level: LLT;Classification code 10006204;Term: Breast carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] Advanced Breast Carcinoma MedDRA version: 14.0;Level: LLT;Classification code 10006204;Term: Breast ...
Trade Name: Yondelis 0.25 mg powder for concentrate for solution for infusion. INN or Proposed INN: trabectedine Trade Name: Yondelis 1 mg powder for concentrate for solution for infusion. INN or Proposed INN: trabectedine Trade Name: Yondelis 0.25 mg powder for concentrate for solution for infusion. INN or Proposed INN: t ...